Organization | Athenex, Inc.

Athenex, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Buffalo NY United States (2003)

Organization Overview

First Clinical Trial

2007

NCT00658970

First Marketed Drug

2003

bumetanide (bumex)

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ATHENEX | Athenex, Inc. | ATHENEX INC | Kinex Pharmaceutical | Kinex Pharmaceuticals | Kinex Pharmaceuticals Inc | Maxinase Life Sciences Ltd.

Active Ingredients

Marketed Drugs (17)

aciclovir (zovirax) (1997)

bumetanide (bumex) (1995)

busulfan (myleran) (2018)

diltiazem (cardizem) (1996)

dipyridamole (persantine) (1998)

doxapram (dopram) (2003)

enalapril (vasotec) (2000)

famotidine (pepcid) (2001)

furosemide (lasix) (2021)

glycopyrronium (robinul) (2020)

lincomycin (lincocin) (2021)

pentobarbital (nembutal) (2017)

prochlorperazine (compazine) (2004)

propranolol (inderal) (2000)

terbutaline (bricanyl) (2004)

tirbanibulin (Klisyri) (2020)

valproic acid (depakene) (2002)

Drugs in Phase 3 Trials (3)

Key: Athenex, Inc. (2) Acquired (1)

cmv-specific t-cells (2 trials)

kx2-391 (8 trials)

paclitaxel (taxol) (4 trials)

Drugs in Phase 2 Trials (4)

Key: Athenex, Inc. (1) Acquired (3)

adenovirus-specific t-cells (1 trial)

cmd-003 (2 trials)

dlx105 (3 trials)

orax (8 trials)

Drugs in Phase 1 Trials (11)

cd19.car-ankt cells (1 trial)

docetaxel (taxotere) (1 trial)

eribulin (halaven) (1 trial)

granisetron (kytril) (1 trial)

kx2-361 (1 trial)

oratecan (1 trial)

pegylated arginine deiminase (1 trial)

pembrolizumab (keytruda) (1 trial)

ramucirumab (cyramza) (1 trial)

tcrt-eso-a2 (1 trial)

topotecan (hycamtin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 1)

Hemangiosarcoma (Phase 1)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 37
# of Trial APIs: 18